Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Domestic Sugammadex for Neuromuscular Blockade Reversal
NCT06334562Recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Muscle relaxation recovery time. Started Jun 2024; status: recruiting.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT06334562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06334562.